Duration of Action of 2 Insulin Glargine Products, LY2963016 and Lantus®, in Subjects with Type I Diabetes Mellitus (T1DM)

被引：0
|
作者：
Heise, Tim
Zhang, Xin
Lam, Eric Chen Quin
Seger, Mary E.
Coutant, David
Chua, Laiyi
Linnebjerg, Helle
机构：
来源：
DIABETES | 2014年 / 63卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
891-P
引用
收藏
页码：A228 / A228
页数：1
相关论文
共 50 条
  • [31] COMPARATIVE PHARMACOKINETICS (PK) AND PHARMACODYNAMICS (PD) OF LY2963016 INSULIN GLARGINE AND EU-AND US-APPROVED VERSIONS OF LANTUS® INSULIN GLARGINE IN HEALTHY SUBJECTS
    Linnebjerg, H.
    Lam, E. C. Q.
    Seger, M.
    Coutant, D.
    Chua, L. Y.
    Chong, C. L.
    Ferreira, M.
    Soon, D.
    Zhang, X.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2014, 106 : S264 - S265
  • [32] Similar Efficacy and Safety of LY2963016 Insulin Glargine and Insulin Glargine (Lantus®) in Patients with T2D in Age Groups (< 65 Yrs,=65 Yrs)
    Pollom, Robyn K.
    Costigan, Timothy
    Lacaya, Lyndon B.
    Ilag, Liza L.
    Hollander, Priscilla A.
    DIABETES, 2016, 65 : A249 - A249
  • [33] Clinical Outcomes of Patients with Diabetes Who Exhibit Upper-Quartile Insulin Antibody Responses After Treatment with LY2963016 or Lantus® Insulin Glargine
    Ilag, Liza L.
    Costigan, Timothy M.
    Deeg, Mark A.
    Pollom, Robyn K.
    Chang, Curtis L.
    Konrad, Robert J.
    Prince, Melvin J.
    DIABETES THERAPY, 2017, 8 (03) : 545 - 554
  • [34] Efficacy and Safety of LY2963016 Insulin Glargine in Chinese Patients with Type 1 Diabetes Previously Treated with Insulin Glargine (Lantus®): a Post Hoc Analysis of a Randomized, Open-Label, Phase 3 Trial
    Xiang Yan
    Chen Feng
    Ying Lou
    Zhiguang Zhou
    Diabetes Therapy, 2022, 13 : 1161 - 1174
  • [35] Clinical Outcomes of Patients with Diabetes Who Exhibit Upper-Quartile Insulin Antibody Responses After Treatment with LY2963016 or Lantus® Insulin Glargine
    Liza L. Ilag
    Timothy M. Costigan
    Mark A. Deeg
    Robyn K. Pollom
    Curtis L. Chang
    Robert J. Konrad
    Melvin J. Prince
    Diabetes Therapy, 2017, 8 : 545 - 554
  • [36] Efficacy and Safety of LY2963016 Insulin Glargine in Chinese Patients with Type 1 Diabetes Previously Treated with Insulin Glargine (Lantus®): a Post Hoc Analysis of a Randomized, Open-Label, Phase 3 Trial
    Yan, Xiang
    Feng, Chen
    Lou, Ying
    Zhou, Zhiguang
    DIABETES THERAPY, 2022, 13 (06) : 1161 - 1174
  • [37] Comparison of the Pharmacokinetics and Pharmacodynamics of LY2963016 Insulin Glargine and EU- and US-Approved Versions of Lantus Insulin Glargine in Healthy Subjects: Three Randomized Euglycemic Clamp Studies
    Linnebjerg, Helle
    Lam, Eric Chen Quin
    Seger, Mary E.
    Coutant, David
    Chua, Laiyi
    Chong, Chew Lan
    Ferreira, Maria M.
    Soon, Danny
    Zhang, Xin
    DIABETES CARE, 2015, 38 (12) : 2226 - 2233
  • [38] Similar efficacy and safety of LY2963016 insulin glargine and insulin glargine (Lantus®) in patients with type 2 diabetes who were insulin-naive or previously treated with insulin glargine: a randomized, double-blind controlled trial (the ELEMENT 2 study)
    Rosenstock, J.
    Hollander, P.
    Bhargava, A.
    Ilag, L. L.
    Pollom, R. K.
    Zielonka, J. S.
    Huster, W. J.
    Prince, M. J.
    DIABETES OBESITY & METABOLISM, 2015, 17 (08): : 734 - 741
  • [39] Patient-reported outcome measures in phase III trials of LY2963016 insulin glargine and reference insulin glargine products: ELEMENT 1 and ELEMENT 2
    Perez-Nieves, Magaly
    Pollom, Robyn K.
    Duan, Ran
    Kabul, Samaneh
    DeLozier, Amy M.
    Kaushik, Puneet
    Lllag, Liza
    GABI JOURNAL-GENERICS AND BIOSIMILARS INITIATIVE JOURNAL, 2018, 7 (02): : 56 - 62
  • [40] Insulin glargine in young patients with type 1 diabetes Mellitus (T1DM): A follow-up study
    D'Annunzio, G
    Minicucci, L
    Felici, E
    Giannattasio, A
    Pistorio, A
    Lorini, R
    DIABETES, 2005, 54 : A666 - A666
12345